Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
News
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an organization committed to democratizing…
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Adaptive Research Appoints Kristin Andruska, MD, PhD as Senior Medical Director and Clinical Neuroscience & Scientific Research Director
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an organization committed to democratizing…
Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in…
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution…
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution…
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
Mr. McEnany will Continue to Serve as Catalyst’s Non-Executive Chairman of the Board Following his…
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
Mr. McEnany will Continue to Serve as Catalyst’s Non-Executive Chairman of the Board Following his…
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts Â
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic…
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts Â
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic…
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…